Clinical Trial Detail

NCT ID NCT02606305
Title Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors ImmunoGen, Inc.
Indications

peritoneum cancer

fallopian tube cancer

ovarian cancer

endometrial cancer

Therapies

Bevacizumab

Carboplatin

Doxorubicin

Mirvetuximab Soravtansine

Age Groups: adult

No variant requirements are available.